TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Success Rate of Lens Centration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Amount of macro/micro atheroma particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Childhood Autism Rating Scale 2nd Edition (CARS2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel movement events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Urinary events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to first detection of atrial fibrillation > 30 seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in parent-reported anxious symptoms at 3 weeks follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in parent-reported anxious symptoms at 6 weeks follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in youth self-reported anxious symptoms at 3 weeks follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in youth self-reported anxious symptoms at 6 weeks follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accumulated incidence of major depression
Endpoint domain: Adverse events/effects
Primary endpoint: Modified MIDAS Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Local tissue damage 30 days after RIPC treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) based on incidence of Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Dimensional accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective effect on DILI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Cognitive function scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pupillary response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: duration of clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ELISA seroconversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Lower Extremity Fugl-Meyer score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ideal technical success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Same Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gastrointestinal Tract Cancer Incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Knee Society Scores Used as Success/Failure Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in the Photoparoxysmal Response (PPR) Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Morning Predose (Trough) Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of Chronic Obstructive Pulmonary Disease (COPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in sensory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of Compassion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Self-Compassion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Fears of Compassion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Social Safeness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change of Emotional Climate at the workplace
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CRP, hs-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful vaginal delivery within 24 hours
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of postpartum depression
Endpoint domain: Adverse events/effects
Primary endpoint: Composite Outcome of Cardiovascular Mortality or Heart Failure Hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative number of new T2-hypertensive lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Standard deviation of Visual Analogue Scale scores for breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Contrast enhancement effect in the early arterial phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Warming sensation and vascular pain
Endpoint domain: Adverse events/effects
Primary endpoint: Pain (Numeric Pain Rating Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical Isometric Muscle Strength (Modified Sphygmomanometer dynamometry)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migraine reduction rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjects' Overall Impression After Using E-Device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usefulness and Reliability of E-Device Functions
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of concordant diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First fracture of hip or femur
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness of Step Rite Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Analgesia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recommended Dose for Expansion (RDFE)
Endpoint domain: Adverse events/effects
Primary endpoint: Adjudicated MACE at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: neurophysiological results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bronchoalveolar Lavage (BAL) Concentration of TNF Alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Visual Analog Scale (VAS) ratings of individualized occupational performance goals
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in number of reflux episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: clinical response to gemtuzumab ozogamicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of NODAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients That Experience Pulmonary Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in lean mass (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuro-Cognitive Screening Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PANSS Positive Negative Syndrome Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anesthesia-related complication
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0-∞ (area under the concentration-time curve of salmeterol in blood plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (maximum measured concentration of salmeterol in blood plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ae0-8 (urinary excretion of tiotropium over an 8 hour interval)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of food safety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitude towards food safety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Practices of food safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in NIHSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Dose-Limiting Toxicity (DLT) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Risky drinking behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Time to CMV Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants for Each of the Eastern Cooperative Oncology Group (ECOG) Performance Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative CD54+ Cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative CD54 Upregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative Total Nucleated Cell (TNC) Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Product Viability (Percentage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local control of the treated lesion(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Distant brain control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Warfarin oral clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Formation clearance of CYP2C9 mediated warfarin metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetics of prucalopride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of insomnia remission
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Prevalence of multisite fibromuscular dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Phase II enzyme expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normal values for HRM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in glucose control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: St. Mark's Incontinence Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sagittal vertebral axis (SVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cervical lordosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Thoracic kyphosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MRI metrics for brain tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of Life rating
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: corneal sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dry eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication Discrepancies
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Extent of absorption (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visceral pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically relevant heart failure events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of detection algorithms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False alarm rate of detection algorithms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on muscle quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: decreased symptoms of inattention, hyperactivity, opposition and defiance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved adaptive functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Heart Rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biomarkers indicating cerebral ischemia in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biomarkers indicating cardiac ischemia in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy for detection of retinal disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilation and perfusion of the lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of participants with treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: NRS pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of plasma ketones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pulmonary change function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in Symptom Checklist for Tic-Symptoms (FBB-TIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of Life (Tic-HRQoL-FBB)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Difference of volumes estimated by geometric indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biological reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in In- and excyclofusion competence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sentinel Lymph Node Uptake Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Relative bioavailability of ALKS 5461
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who become critically ill
Endpoint domain: Mortality/survival
Primary endpoint: incidence of lack anticipated Hb response or loss of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: occurrence of PRCA and other immunogenicity related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: rate of engagement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Percent Change in Total Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Geometric Mean Titer for Anti-JEV Neutralizing Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titer for Hepatitis A Virus Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recommended phase 2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Collectivism or individualism level
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: glycocalyx proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to next bronchitis episode
Endpoint domain: Adverse events/effects
Primary endpoint: monthly seizure frequency after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: interruption of status epilepticus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Weight in kilograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical functioning measured by a 6-minute walk test
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Zanarini Rating Scale for Borderline Personality Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response, Stable Disease, or Progressive Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage Change in P1NP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage Change in BSAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Circulating 25OHD concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BOLD signal between painful memories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BOLD signal between emotional memories not painful
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BOLD signal between neutral memories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BOLD signal between control test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: System Performance Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Geriatric Depression Scale (GDS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Falls Experienced by Participants Over Twelve Months of Surveillance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Congenital Abnormalities detected after birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing abnormalities measured after birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual abnormalities measured after birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Abnormal Microbiome Bacterial Sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal Endometrial Receptivity Array
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized Microbiome Bacterial Sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized Endometrial Receptivity Array
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Inventory of Psychosocial Functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: steady-state pharmacokinetics of nelfinavir and M8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beck's Depression Inventory total score after rTMS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of follicle-stimulating hormone (FSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of estradiol (E2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of Anti-mullerian hormone (AMH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of Inhibin B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of antral follicular count (AFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Field Mean Deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal Nerve Fiber Layer (RNFL) Thickness Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Cup to Disc Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Management of anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Management of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the semaglutide plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Operative Oswestry Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Size of Adipocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Reaction Velocity (Vmax) for Facilitated LCFA Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Critical Temperature Thresholds (CTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Spontaneous Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes